As part of the continual commitment to further research on Enzyme Indicators, Protak have commissioned Public Health England to further study tAK Enzyme Indicators. Over the next 12 months Protak and PHE will be working with select pharmaceutical partners to introduce the revolutionary Enzyme Indicators. The trial partners will gain huge and invaluable insight into exactly what advances this key technology brings. Not only will the trial partners benefit from insider knowledge, the EI trial partners will be guaranteed first and initially exclusive access to our complete data centres. If you would like more information on the trial then please contact us.